Ultrarapid Lispro (Lyumjev) Has an Improved Pharmacokinetic Profile for Exercise Compared With Humalog, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion
Using Lyumjev in conventional CSII pump therapy provides more effective BRRs prior to exercise compared with Humalog, with fewer hypoglycemic events in active adults with type 1 diabetes.
Authors
- Alexander Abitbol (ORCID: https://orcid.org/0000-0001-6830-3532)
- Elizabeth LaBell
- Jennifer Leohr (ORCID: https://orcid.org/0000-0001-5434-7905)
- David E. Coutant (ORCID: https://orcid.org/0000-0002-6291-5623)
- ARITRA GHOSH
- Michael C. Riddell
- Lauren V. Turner
Institutions
- Eli Lilly (United States) (US)
- York University (CA)
- LMC Diabetes & Endocrinology (Canada) (CA)
Publication Details
- Journal
- Diabetes Care
- Published
- 2026-03-26
- DOI
- https://doi.org/10.2337/dc25-2294
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00